AU2010306750B2 - Sepiapterin reductase inhibitors for the treatment of pain - Google Patents

Sepiapterin reductase inhibitors for the treatment of pain Download PDF

Info

Publication number
AU2010306750B2
AU2010306750B2 AU2010306750A AU2010306750A AU2010306750B2 AU 2010306750 B2 AU2010306750 B2 AU 2010306750B2 AU 2010306750 A AU2010306750 A AU 2010306750A AU 2010306750 A AU2010306750 A AU 2010306750A AU 2010306750 B2 AU2010306750 B2 AU 2010306750B2
Authority
AU
Australia
Prior art keywords
mmol
compound
pain
reaction mixture
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010306750A
Other languages
English (en)
Other versions
AU2010306750A1 (en
Inventor
Julian Blagg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of AU2010306750A1 publication Critical patent/AU2010306750A1/en
Application granted granted Critical
Publication of AU2010306750B2 publication Critical patent/AU2010306750B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
AU2010306750A 2009-10-15 2010-10-14 Sepiapterin reductase inhibitors for the treatment of pain Ceased AU2010306750B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25201309P 2009-10-15 2009-10-15
US61/252,013 2009-10-15
PCT/US2010/052674 WO2011047156A1 (en) 2009-10-15 2010-10-14 Sepiapterin reductase inhibitors for the treatment of pain

Publications (2)

Publication Number Publication Date
AU2010306750A1 AU2010306750A1 (en) 2012-05-17
AU2010306750B2 true AU2010306750B2 (en) 2014-11-13

Family

ID=43876540

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010306750A Ceased AU2010306750B2 (en) 2009-10-15 2010-10-14 Sepiapterin reductase inhibitors for the treatment of pain

Country Status (6)

Country Link
US (2) US9169234B2 (enExample)
EP (1) EP2488025A4 (enExample)
JP (1) JP5758395B2 (enExample)
AU (1) AU2010306750B2 (enExample)
CA (1) CA2777782C (enExample)
WO (1) WO2011047156A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2049520A4 (en) 2006-08-07 2011-01-05 Ironwood Pharmaceuticals Inc indole compounds
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
CN102329263A (zh) * 2011-10-17 2012-01-25 上海化学试剂研究所 一种n-乙酰基-5-甲氧基色胺的制备方法
BR112015025686B1 (pt) 2013-04-15 2020-10-27 Fmc Corporation composto, composições fungicidas e método para o controle das doenças dos vegetais
WO2015071230A1 (en) * 2013-11-15 2015-05-21 Bayer Cropscience Ag Catalytic hydrogenation of nitriles
US10365267B2 (en) * 2014-10-31 2019-07-30 Children's Medical Center Corporation Methods and assays relating to sepiapterin reductase inhibition
ES2969565T3 (es) * 2015-09-30 2024-12-13 Max Planck Ges Zur Foerderung Derwissenschaften E V Derivados heteroarílicos como inhibidores de la sepiapterina reductasa
WO2017131601A1 (en) * 2016-01-26 2017-08-03 Ataturk Universitesi Bilimsel Arastirma Projeleri Birimi N3,n6-bis(2-(5-methoxy-1h-indole-3-yl)ethyl)-2,6-dimethyl-4-(2-nitrophenyl)pyridine-3,5-dicarboxamide and use thereof in the field of neurotoxicity
US20170291372A1 (en) * 2016-04-09 2017-10-12 Velo3D, Inc. Generating three-dimensional objects by three-dimensional printing with rotation
NZ745936A (en) 2016-04-27 2020-02-28 Univ Puerto Rico 1,5-disubstituted 1,2,3-triazoles are inhibitors of rac/cdc42 gtpases
DK3558944T3 (da) 2016-12-21 2022-05-30 Bayer Cropscience Ag Hydrogenering af et substitueret 2-methylcyanopyridylderivat i nærvær af en raney-cobaltkatalysator
WO2019175332A1 (en) 2018-03-14 2019-09-19 Imba - Institut Für Molekulare Biotechnologie Gmbh Bh4 pathway inhibition and use thereof for treating t-cell mediated autoimmune diseases or hypersensitivity
CN108689856A (zh) * 2018-07-09 2018-10-23 上海华堇生物技术有限责任公司 一种3-羟基-β-硝基苯乙烯的新制备方法
US11270771B2 (en) * 2019-01-29 2022-03-08 Silicon Storage Technology, Inc. Neural network classifier using array of stacked gate non-volatile memory cells
EP4219500A4 (en) 2020-04-14 2024-10-23 Nissan Chemical Corporation FUSED HETEROCYCLIC COMPOUND
WO2022104475A1 (en) 2020-11-19 2022-05-27 Magicmed Industries Inc. Nitrilated psilocybin derivatives and methods of using
JP2024516279A (ja) * 2021-05-05 2024-04-12 カレ ケミカル テクノロジーズ インコーポレイテッド 触媒トリプタミンプロセスおよび前駆体
CN113214133B (zh) * 2021-05-08 2023-03-07 河北维达康生物科技有限公司 一种褪黑素的合成方法
CN113960317A (zh) * 2021-08-19 2022-01-21 深圳市辅酶医科技有限公司 一种测量生物样品中nad+浓度的生物传感器及方法
CN113788780B (zh) * 2021-10-15 2023-06-16 河北维达康生物科技有限公司 一种n-乙酰基-5-甲氧基色胺的合成方法
EP4551211A1 (en) 2022-07-08 2025-05-14 Institut Curie Serotonin analogues for use in treating metalloptosis-associated disorders
JP2025172328A (ja) * 2024-05-13 2025-11-26 和彦 中村 Ｉｇｆ－１産生促進剤およびその応用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050197341A1 (en) * 2003-11-13 2005-09-08 Woolf Clifford J. Methods for treating pain

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437398A1 (fr) * 1978-06-20 1980-04-25 Commissariat Energie Atomique Compose iode utilisable comme traceur en radio-immunologie
DE3613623A1 (de) 1986-04-23 1987-10-29 Bayer Ag N-dihydroindolylethyl-sulfonamide
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
EP0620222A3 (en) * 1993-04-14 1995-04-12 Lilly Co Eli Tetrahydro-beta-carbolines.
EP0746544B1 (en) 1994-02-22 1998-09-09 Merrell Pharmaceuticals Inc. Novel indole derivatives useful to treat estrogen-related neoplasms and disorders
CA2241666C (en) * 1996-03-08 2007-11-06 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
RU2141483C1 (ru) * 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
US6306890B1 (en) 1999-08-30 2001-10-23 Vanderbilt University Esters derived from indolealkanols and novel amides derived from indolealkylamides that are selective COX-2 inhibitors
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
GB0031315D0 (en) * 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
US6593331B2 (en) 2001-04-17 2003-07-15 Laboratories Upsa Method for treatment of pain
EP1406872B1 (en) * 2001-06-20 2007-12-19 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
TWI334778B (en) * 2001-12-03 2010-12-21 Wyeth Corp Inhibitors of cytosolic phospholipase a2
DE10252665A1 (de) 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
US7084154B2 (en) * 2003-02-11 2006-08-01 Pharmacopeia Drug Disclovery, Inc. 2-(aminomethyl) arylamide analgesics
US7074775B2 (en) * 2004-09-14 2006-07-11 Miller Landon C G Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders
AU2005313108B2 (en) 2004-12-10 2011-05-26 Msd Italia S.R.L. Heterocycle derivatives as histone deacetylase (HDAC) inhibitors
KR20080033298A (ko) * 2005-07-12 2008-04-16 바이엘 크롭사이언스 소시에떼아노님 벤조헤테로시클릴에틸카르복사미드 유도체
MX2008001964A (es) 2005-08-10 2008-03-26 Novartis Ag Metodo de uso de inhibidores de desacetilasa.
US7902251B2 (en) * 2005-10-19 2011-03-08 Allergan, Inc. Method for treating pain
AU2006319245A1 (en) 2005-12-01 2007-06-07 F. Hoffmann-La Roche Ag Novel vinylogous acids derivatives
AU2006323700B2 (en) 2005-12-05 2011-02-17 Otsuka Pharmaceutical Co., Ltd. Diarylether derivatives as antitumor agents
JP5142513B2 (ja) * 2005-12-05 2013-02-13 大塚製薬株式会社 医薬
JP5089185B2 (ja) * 2006-02-02 2012-12-05 大塚製薬株式会社 コラーゲン産生抑制剤。
FR2898358B1 (fr) 2006-03-08 2008-05-30 Macef Sa Association d'un antagoniste du recepteur 5ht2 et d'activateur du recepteur 5ht2 par modulation allosterique et leurs utilisations comme produits medicaux
RU2303597C1 (ru) * 2006-05-12 2007-07-27 Иващенко Андрей Александрович Фармацевтическая композиция, способы ее получения и применения
US20080009485A1 (en) * 2006-05-26 2008-01-10 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2 in the treatment of thrombosis
US7893055B2 (en) * 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
EP2044056B1 (en) * 2006-07-14 2012-08-22 Novartis AG Pyrimidine derivatives as alk-5 inhibitors
EP2049520A4 (en) 2006-08-07 2011-01-05 Ironwood Pharmaceuticals Inc indole compounds
AR063302A1 (es) 2006-10-13 2009-01-21 Otsuka Pharma Co Ltd Derivados de 4-benzo[b]tiofen-4-il-piperazin-1-il con accion antagonista del receptor 5-ht2a de serotonina y receptor de adrenalina alfa1 y agonista parcial del receptor d2, una composicion farmaceutica que lo comprende y un proceso para producirla.
JP2008115175A (ja) * 2006-10-13 2008-05-22 Otsuka Pharmaceut Co Ltd 複素環化合物
FR2907451B1 (fr) 2006-10-18 2008-12-12 Servier Lab "nouveaux derives indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
WO2008073825A1 (en) 2006-12-08 2008-06-19 Exelixis, Inc. Lxr and fxr modulators
US20080287452A1 (en) 2007-05-16 2008-11-20 Wyeth Heteroaryl/aryl pyrimidine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
TW200914437A (en) * 2007-06-20 2009-04-01 Ironwood Pharmaceuticals Inc FAAH inhibitors
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
RU2373934C1 (ru) * 2008-03-19 2009-11-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств
GB0910003D0 (en) * 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050197341A1 (en) * 2003-11-13 2005-09-08 Woolf Clifford J. Methods for treating pain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SMITH, G. K. et al. J. Biol. Chem. (1992), 267(8), 5599-5607 *

Also Published As

Publication number Publication date
WO2011047156A1 (en) 2011-04-21
US20120322800A1 (en) 2012-12-20
EP2488025A4 (en) 2013-04-03
US9169234B2 (en) 2015-10-27
US20160031812A1 (en) 2016-02-04
US10059664B2 (en) 2018-08-28
CA2777782A1 (en) 2011-04-21
JP5758395B2 (ja) 2015-08-05
EP2488025A1 (en) 2012-08-22
CA2777782C (en) 2016-06-28
JP2013508288A (ja) 2013-03-07
AU2010306750A1 (en) 2012-05-17

Similar Documents

Publication Publication Date Title
CA2777782C (en) Sepiapterin reductase inhibitors for the treatment of pain
CN108383836B (zh) 作为mek抑制剂的杂环基化合物
JP2025131575A (ja) Ｍａｓ関連ｇタンパク質受容体ｘ４のモジュレーターおよび関連製品ならびに方法
JP5298022B2 (ja) 有機化合物
JP5826972B2 (ja) 酸セラミダーゼインヒビターおよびそれらの医薬としての使用
WO2004092117A1 (en) Para-sulfonyl substituted phenyl compounds as modulators of ppars
WO2009112445A1 (en) Method of increasing cellular phosphatidyl choline by dgat1 inhibition
WO2005115983A1 (en) Aryl sulfonamide and sulfonyl compounds as modulators of ppar and methods of treating metabolic disorders
CN103476776A (zh) 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
JP2024528251A (ja) Ｈｄａｃとｎａｄ合成を標的とする多標的阻害剤及びその用途
JP2007508364A (ja) Ｅｐ４受容体拮抗薬としてのフラン誘導体
CN117295734A (zh) 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
CN114206868B (zh) 作为hdac6抑制剂的3-(2-(杂芳基)-吡啶-4-基)-5-(三氟甲基)-1,2,4-噁二唑衍生物
WO2011035009A1 (en) Heterocyclic gtp cyclohydrolase 1 inhibitors for the treatment of pain
WO2004092130A2 (en) N-containing heteroaromatic compounds as modulators of ppars and methods of treating metabolic disorders
JP6170260B2 (ja) ５−ｈｔ２ｂアンタゴニスト
JP7624745B2 (ja) Ｔｒｐｖ４受容体リガンド
KR20240124376A (ko) 벤젠 설폰아미드 티아졸 화합물과 이들의 암 치료 용도
CN103298344A (zh) 整链蛋白偶联性激酶抑制剂
CN119912442A (zh) 2,4-二取代噻二唑衍生物及其作为gls1抑制剂的用途
BR112020010534A2 (pt) derivados de 1,2,4-oxadiazol como inibidores de histona desacetilase 6

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired